Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Cash from Financing Activities (2020 - 2025)

RxSight (RXST) has disclosed Cash from Financing Activities for 6 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 64.28% year-over-year to $1.1 million, compared with a TTM value of $1.9 million through Dec 2025, down 98.49%, and an annual FY2025 reading of $1.9 million, down 98.49% over the prior year.
  • Cash from Financing Activities was $1.1 million for Q4 2025 at RxSight, up from -$530000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $120.5 million in Q3 2021 and bottomed at -$8.2 million in Q3 2023.
  • Average Cash from Financing Activities over 5 years is $16.5 million, with a median of $1.6 million recorded in 2025.
  • The sharpest move saw Cash from Financing Activities soared 231721.15% in 2021, then crashed 1709.67% in 2023.
  • Year by year, Cash from Financing Activities stood at $404000.0 in 2021, then surged by 1461.14% to $6.3 million in 2022, then plummeted by 43.52% to $3.6 million in 2023, then decreased by 16.45% to $3.0 million in 2024, then tumbled by 64.28% to $1.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RXST at $1.1 million in Q4 2025, -$530000.0 in Q3 2025, and $2.1 million in Q2 2025.